Annual Meeting

Degrading the mighty proteome with small molecules

Katherine A. Donovan will speak at the Discover BMB Molecular & Cellular Proteomics session
Kanika Khanna
Feb. 23, 2023

Katherine Donovan’s research path hasn’t followed a linear trajectory; she’s zig-zagged from doing basic biochemical studies to proteomics-based translational research. In her words, she is now “designing small molecules to hijack the cell’s waste disposal system and redirect it to disease-causing proteins.”

Katherine Donovan
Katherine Donovan

But Donovan’s movements have not been random, she said: “I’ve found that I gravitate toward collaborative interactions.”

During her Ph.D. at the University of Canterbury in New Zealand, Donovan studied the adaptive evolution of pyruvate kinases in E. coli. Using biochemistry and structural biology techniques, she demonstrated how mutations in the protein make the bacterium better able to tolerate low-glucose conditions.

After joining Eric Fischer’s lab at the Dana–Farber Cancer Institute in 2016, Donovan used proteomics to quantify changes in protein expression in mammalian cells when perturbed with drugs and small molecules. Her desire for collaboration motivated her to join Dana–Farber’s new Center for Protein Degradation, or CPD, in November 2018. There she built and managed the proteomics operation and developed novel technologies to advance drug discovery for different targets.

Now a lead scientist in the Fischer lab, Donovan spearheads multiple projects in proteomics as well as serving as a proteomics advisor to the CPD. Many of her projects are focused on finding degradation therapeutics for proteins involved in diseases such as cancer and Alzheimer’s.

Donovan’s favorite part about research is the community she gets to interact with daily. “People are the biggest driver in my job,” she said. “I am very lucky to have a fantastic proteomics team where everyone is super excited about science.”

Designing degradable molecules

Cells rid themselves of misfolded proteins by a process in which the proteins are ubiquitinated by the E3 ligase complex and degraded by the 26S proteasome. This pathway can be hijacked by using small-molecule degraders to recruit E3 ligases artificially to proteins linked to diseases. This process, called targeted protein degradation, or TPD, offers several advantages over conventional inhibition strategies: proteins of interest can be eliminated completely, and TPD has the potential to target a large portion of the proteome that previously was considered undruggable.

Katherine Donovan and her team at the Dana–Farber Cancer Institute recently used a chemoproteomics pipeline to identify degradable kinases by designing the degrader molecules to be as promiscuous as possible. Mutations in kinases are at the root of many human diseases, and before this project, only 7% of the human kinome was reported as degradable, making kinases attractive candidates for TPD. The team prepared a library of 91 potential kinase degrader molecules and, using proteomics, found that they degraded about 200 distinct kinases.

The researchers released their data set as a public resource to advance the field of TPD.

“Our group saw how hard it was to design these molecules and how much time, effort and money was put in,” Donovan said. “One of the ways in which we can advance the field and help other researchers is by making the data available to everyone. Science moves faster if you take a community approach.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Kanika Khanna

Kanika Khanna is the scientific program leader at the Gladstone Institute of Virology. She earned her Ph.D. at University of California, San Diego. She is passionate about science outreach and communication and likes to crochet and hike in her free time.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Finding a symphony among complex molecules
Profile

Finding a symphony among complex molecules

April 23, 2025

MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.

Sketching, scribbling and scicomm
Science Communication

Sketching, scribbling and scicomm

April 16, 2025

Graduate student Ari Paiz describes how her love of science and art blend to make her an effective science communicator.

Embrace your neurodivergence and flourish in college
Diversity

Embrace your neurodivergence and flourish in college

April 14, 2025

This guide offers practical advice on setting yourself up for success — learn how to leverage campus resources, work with professors and embrace your strengths.

Survival tools for a neurodivergent brain in academia
Essay

Survival tools for a neurodivergent brain in academia

April 10, 2025

Working in academia is hard, and being neurodivergent makes it harder. Here are a few tools that may help, from a Ph.D. student with ADHD.

Quieting the static: Building inclusive STEM classrooms
Interview

Quieting the static: Building inclusive STEM classrooms

April 8, 2025

Christin Monroe, an assistant professor of chemistry at Landmark College, offers practical tips to help educators make their classrooms more accessible to neurodivergent scientists.

Hidden strengths of an autistic scientist
Essay

Hidden strengths of an autistic scientist

April 3, 2025

Navigating the world of scientific research as an autistic scientist comes with unique challenges —microaggressions, communication hurdles and the constant pressure to conform to social norms, postbaccalaureate student Taylor Stolberg writes.